Sensei Biotherapeutics’ (SNSE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a report published on Wednesday,Benzinga reports. They currently have a $4.00 target price on the stock.

Sensei Biotherapeutics Stock Performance

SNSE stock opened at $0.51 on Wednesday. Sensei Biotherapeutics has a one year low of $0.38 and a one year high of $1.94. The firm’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.56. The firm has a market cap of $12.89 million, a PE ratio of -0.43 and a beta of 0.17.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI raised its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the period. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.